Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 7;22(45):9954–9965. doi: 10.3748/wjg.v22.i45.9954

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Mipomersen exerts a dose-dependent and potent anti-hepatitis C virus effect. A: Huh7/CD81 high cells were treated with escalating doses of mipomersen from 200 ug/mL to 1000 ug/mL and then infected with JFH1. At 72 h following infection, there was a dose-dependent inhibition of hepatitis C virus (HCV), demonstrated at both the RNA and protein (HCV core) level. Data are shown as means with 95%CI (^aP < 0.05); B: OR6 genotype 1b replicon cells were treated with mipomersen for 72 h and no effect was observed on HCV replication; C: There was no negative impact of escalating doses of mipomersen on cell viability; D: Infectivity of the virus was assessed using the TCID50 method. Virus generated in cells treated with mipomersen had a significant reduction in infectivity compared with virus generated in mock-treated cells. Data shown as mean TCID50/mL ± SEM.